News

A Mass General-led analysis of claims data indicates less than 1-in-10 patients who suffer a hip fracture were prescribed an osteoporosis treatment in the next 6 months, while also providing data on trends in prescribing practices of newer agents.

Guselkumab is the first and only approved IL-23 inhibitor therapy used to treat adults with active PsA and moderate to severe plaque psoriasis (PsO). The medication showed efficacy in skin clearance and joint symptom relief and passed safety measures. Additionally, physical function, health-related quality of life, and resolution of enthesitis and dactylitis were confirmed through week 100.

The diagnosis of psoriatic arthritis (PsA) may be delayed by more than 2 years in half of patients, especially those of younger age at symptom onset, or with a higher body mass index (BMI) or enthesitis before diagnosis.

A majority of patients with active psoriatic arthritis achieved and maintained skin clearance, joint symptom relief through year 2 of treatment.

Using data from the Osteoporotic Fractures in Men study, new research suggests incorporating AAC scores and PVFx could help predict older men at increased risk of fractures.

Although associated with adverse effects, glucocorticoids are effective for managing rheumatoid arthritis (RA) symptoms and are prescribed to most patients. Test your knowledge of the prescription of glucocorticoids in RA with this quiz.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 12, 2021.

Pegloticase (pegylated uricase) is medication approved by the US Food and Drug Administration (FDA) designed to lower sUA in patients with uncontrolled gout. However, 26% of patients have infusion-related reactions (IRs), which may be indicative of the development of antidrug antibodies (ADAs). Due to this, physicians often administer immunomodulators in addition to pegloticase in order to prevent ADAs as well as increase the effectiveness of the therapy.

There were no differences in the occurrence of clinical characteristics between the subset of patients with and without neurological involvement, however disease activity was slightly higher in patients with neurological involvement than those without. Additionally, anti-SSA antibody was significantly higher in patients with neurological involvement and anti-SSB autoantibody was lower.

Older adults who self-report rheumatoid arthritis (RA) do not have a Medicare claims history consistent with their diagnosis, according to study.

Subcutaneous injection of tocilizumab has been shown to improve the rate of lung function in patients with systemic sclerosis-induced interstitial lung disease when compared with a placebo.

Research suggests that adults who experienced 2 or more traumatic events during childhood are at a 100% increased risk to develop rheumatic disease.

In patients with psoriatic arthritis refractory or intolerant to biologic disease-modifying antirheumatic drugs (DMARDs), upadacitinib (Abbvie; Rinvoq) 15 mg and 30 mg once per day was more effective than placebo over 24 weeks in improving signs and symptoms of psoriatic arthritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 5, 2021.

The indication makes the IL-6 inhibitor the first biologic approved for treating pulmonary function in patients with the rare disease.

Readers may be surprised to hear that a high percentage of health professionals, about 70%, find it difficult to develop empathy with their patients.

Patients with rheumatoid arthritis (RA) believe that prednisolone is a necessary medication, yet they are cautious about taking it due to the adverse effects, according to a new study.

An analysis of data from the Veterans Health Administration is providing insight into the apparent increase in risk of fracture or osteoporosis among older adults with kidney or ureteral stones.

Investigators believe inflammation, which is known to begin before rheumatoid arthritis (RA) symptoms appear, may be a main factor in the increased prevalence and incidence in multimorbidity for patients with RA.

In the second portion of this series, Dr. Concoff discusses the path forward in the evaluation and treatment of systemic lupus erythematosus (SLE).

Trials testing hydroxychloroquine against COVID-19 have produced mixed results.

An analysis of more than 30k middle-aged adults from a prospective cohort study in Sweden is providing insight into the effects of exercise and other variables on fracture risk in these patients.

“We found that initiation of febuxostat administration during an acute gout flare did not prolong acute flares, and the rate of ‘treat to target’ was higher in the febuxostat group,” investigators concluded. “This may increase patient compliance.”

Some treatments for rheumatic diseases have shown promise for treating COVID-19, but many should be avoided in patients with confirmed or suspected COVID-19. How much do you know about the use of treatments for rheumatic diseases in patients with COVID-19? Take our quiz to find out.

Investigators explored the connection between patients with systemic lupus erythematosus (SLE) and an increased risk of asthma and chronic obstructive pulmonary disease (COPD), which concurrently correlated with worse patient-reported outcomes (PROs) cross-sectionally.

Improvements for pain did not sustain at the 12 month follow-up.

Generally, guidelines recommend beginning psoriatic arthritis (PsA) treatment with tumor necrosis factor inhibitors (TNFis). However, not all patients respond to this method. Ixekizumab (IXE) improved the signs and symptoms of PsA in patients who had exhibited inadequate response to 1 or 2 TNFis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 19, 2021.

The American College of Rheumatology (ACR) has published guidance regarding coronavirus disease 2019 (COVID-19) vaccination for patients with rheumatic diseases, with emphasis placed on prioritizing immunocompromised patients to receive the vaccine.